Proventricular Dilatation Disease (PDD)

The name 'macaw wasting syndrome' reflects how this disease was first recognized clinically — large macaws presenting with progressive weight loss and passing undigested food, despite eating normally or even ravenously, because the food was passing through a gut that could no longer move it properly. The condition has since been documented across a wide range of parrot species, from cockatoos and African greys to conures and lovebirds, and the clinical name proventricular dilatation disease reflects the mechanism rather than the species where it was first described: the proventriculus, the glandular 'true stomach' that sits between a bird's crop and gizzard, loses its normal muscular contractions and dilates, sometimes dramatically, because the nerves that coordinate that motility have been damaged.

The discovery of avian bornavirus as the causative agent, published by two independent research groups in 2008, resolved a question that had puzzled avian veterinarians since PDD was first described in the late 1970s. ABV is a negative-strand RNA virus in the family Bornaviridae, and at least several genotypes have been identified in parrots, which may partly explain why the disease's presentation and progression vary so much between individual birds — some genotypes appear more consistently associated with clinical disease than others in the research literature, though this remains an active area of study.

What makes PDD genuinely difficult to manage, compared to most infectious diseases covered on this site, is the gap between infection and clinical disease. A bird can be infected with ABV, test positive on PCR, and shed the virus in droppings for months or years while showing no outward signs at all, then develop clinical PDD later — or never develop it. This means a flock or household can have an asymptomatic carrier bird quietly present for a long time before any bird shows the symptoms that would prompt testing, and it's a major reason repeated PCR testing over time is recommended for at-risk collections rather than a single screening test being treated as reassurance.

Clinically, PDD shows up in two overlapping ways, and a given bird may show one, the other, or both as the disease progresses. The gastrointestinal form presents as chronic regurgitation, passing recognizable whole seed or undigested food in droppings (a genuinely distinctive and concerning sign that's worth photographing to show a vet), a crop that empties slowly, and progressive weight loss that persists even when appetite looks completely normal — the food simply isn't being processed and absorbed the way it should be. The neurological form reflects the same underlying nerve inflammation reaching the central nervous system: incoordination, abnormal or repetitive head movements, tremors, seizures, and sometimes a fairly sudden behavioral or personality change that owners describe as the bird 'not seeming like itself.'

Diagnosis is genuinely difficult and typically requires more than one line of evidence together. A crop or proventricular biopsy showing the characteristic lymphoplasmacytic nerve inflammation remains one of the more definitive diagnostic tools, though a negative biopsy doesn't fully rule out the disease since the lesions can be patchy. PCR testing for ABV in blood, feces, or crop swab can detect active viral shedding but, as above, a positive result confirms infection without confirming clinical PDD, and a negative result doesn't rule out infection given intermittent shedding. Contrast radiography (a barium series) can show a dilated, slow-emptying proventriculus consistent with the disease. Most avian specialists interpret these tools together with the clinical picture rather than relying on any single test in isolation.

Management, once a bird is showing clinical signs, is realistically about quality of life and slowing progression rather than reversal. Anti-inflammatory treatment aimed at reducing the underlying nerve inflammation has become a mainstay of supportive protocols in recent years and appears, anecdotally and in some published case series, to meaningfully extend stable periods for some birds — though it is not a cure and response varies bird to bird. Nutritional support matters enormously: a bird losing the ability to move food through a dilated proventriculus needs calorie-dense, easily digestible food, sometimes in smaller more frequent portions, and in more advanced cases needs assisted feeding to maintain body condition at all.

For anyone keeping multiple parrots, or considering adding a new bird to an existing household, PDD is one of the clearest arguments for genuine quarantine practice rather than a token few days of separate housing. A new bird ideally spends an extended quarantine period (commonly discussed in the 30-90 day range depending on the source and the bird's risk profile) in fully separate airspace from existing birds, with repeat PCR testing during that window, before any direct or airborne contact is allowed. This is inconvenient and it is also the single most effective tool available to protect an existing flock from an asymptomatic carrier.

PDD's prognosis is genuinely variable in a way that's important to be honest about rather than smoothing over: some birds diagnosed with clinical PDD, particularly those caught early and managed with anti-inflammatory and nutritional support, remain stable for months to a few years with a reasonable quality of life. Others, especially those presenting primarily with neurological signs or diagnosed only after significant weight loss has already occurred, progress more quickly despite treatment. There is currently no way to reliably predict, at diagnosis, which course a given bird will follow.

The gastrointestinal-predominant presentation tends, on average, to be more manageable for longer than the neurological-predominant presentation, because nutritional support can meaningfully offset a slow-emptying proventriculus in a way that's harder to offset for progressive seizures or severe incoordination — but this is a general pattern, not a rule, and plenty of exceptions exist in individual cases documented in the literature and in specialist practice.

Because there is no cure, the honest long-term conversation with an avian vet after a PDD diagnosis is about a management plan and a realistic sense of what decline looks like for this disease, so that quality-of-life decisions can be made proactively rather than in a crisis. This is not a disease where 'fighting it as hard as possible' and 'accepting a terminal diagnosis and focusing on comfort' are opposed — for many birds the two blend into the same supportive-care plan for an extended period.

For the rest of a household's birds, a confirmed PDD case changes the calculus considerably: testing and monitoring the exposed birds, even if asymptomatic, becomes reasonable given how long asymptomatic shedding can persist, and any future new-bird introductions warrant the fuller quarantine-and-repeat-testing protocol rather than a shortened one.

Research into ABV and PDD is genuinely active, including work on genotype-specific pathogenicity and on refining anti-inflammatory protocols, so the management picture has measurably improved over the past decade and may continue to. A diagnosis today is not the same prognosis conversation it would have been fifteen years ago, before the causative virus was even identified — but it remains a serious, currently incurable disease, and framing it that way with an owner from the outset serves them better than false reassurance.